{"filepath": "../L2M3_data/0_csd_related_papers/ACS_XML/ml9b00284.xml", "publisher": "acs", "elements": [{"idx": 1, "type": "text", "classification": "error", "content": "<p>Five innovative ternary\ncopper\u00ad(II) complexes [Cu\u00ad(OH-PIP)\u00ad(Phe)\u00adCl]\u00ad(<bold>1</bold>), [Cu\u00ad(OH-PIP)\u00ad(Gly)\u00ad(H<sub>2</sub>O)]\u00adNO<sub>3</sub>\u00b72H<sub>2</sub>O (<bold>2</bold>), [Cu\u00ad(OH-PIP)\u00ad(Ala)\u00ad(Cl)]\u00b7H<sub>2</sub>O (<bold>3</bold>), [Cu\u00ad(OH-PIP)\u00ad(Met)]\u00adPF<sub>6</sub>\u00b72H<sub>2</sub>O (<bold>4</bold>), and [Cu\u00ad(OH-PIP)\u00ad(Gln)\u00ad(H<sub>2</sub>O)]\u00ad(Cl)\u00b73H<sub>2</sub>O (<bold>5</bold>) have been synthesized and characterized\nby infrared spectroscopy, elemental analysis, and single crystal X-ray\ndiffraction analysis. X-ray crystallography indicates that all Cu\natoms are five-coordinated in a square-pyramidal configuration. The\ncomplexes have been screened for cytotoxicity against human breast\ncancer cell lines MCF-7, MDA-MB-231, and CAL-51. The best anticancer\nactivity is obtained with triple-negative breast cancer CAL-51 and\nMDA-MB-231 cell lines, with IC<sub>50</sub> values in the range of\n0.082\u20130.69 \u03bcM. Importantly, the copper compounds were\nmore effective than carboplatin at triggering cell death. Mechanistically,\nthe complexes inhibit proteasomal chymotrypsin-like activity, and\ndocking studies reveal their 20S proteasome binding sites. As a consequence,\nthey cause the accumulation of ubiquitinated proteins, inhibit cell\nproliferation, and induce apoptosis. In addition, these copper complexes\ndecrease the stemness of triple-negative breast cancer cells and have\nsynergistic effects with CBP on TNBC cells, indicating their great\npotential as a novel therapy for triple-negative breast cancer.</p>", "clean_text": "Five innovative ternary copper(II) complexes [Cu(OH-PIP)(Phe)Cl](1), [Cu(OH-PIP)(Gly)(H2O)]NO3\u22c52H2O (2), [Cu(OH-PIP)(Ala)(Cl)]\u22c5H2O (3), [Cu(OH-PIP)(Met)]PF6\u22c52H2O (4), and [Cu(OH-PIP)(Gln)(H2O)](Cl)\u22c53H2O (5) have been synthesized and characterized by infrared spectroscopy, elemental analysis, and single crystal X-ray diffraction analysis. X-ray crystallography indicates that all Cu atoms are five-coordinated in a square-pyramidal configuration. The complexes have been screened for cytotoxicity against human breast cancer cell lines MCF-7, MDA-MB-231, and CAL-51. The best anticancer activity is obtained with triple-negative breast cancer CAL-51 and MDA-MB-231 cell lines, with IC50 values in the range of 0.082-0.69 \u03bcM. Importantly, the copper compounds were more effective than carboplatin at triggering cell death. Mechanistically, the complexes inhibit proteasomal chymotrypsin-like activity, and docking studies reveal their 20S proteasome binding sites. As a consequence, they cause the accumulation of ubiquitinated proteins, inhibit cell proliferation, and induce apoptosis. In addition, these copper complexes decrease the stemness of triple-negative breast cancer cells and have synergistic effects with CBP on TNBC cells, indicating their great potential as a novel therapy for triple-negative breast cancer.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else]"}}, {"idx": 2, "type": "text", "classification": ["else"], "content": "<p>The ubiquitin-proteasome system\n(UPS) plays an important role in a multitude of cellular processes\nincluding cell cycle progression, apoptosis, angiogenesis, DNA damage\nand repair, drug resistance, and differentiation. The 20S proteasome is a high molecular weight protease\ncomplex with a proteolytic core containing \u03b21, \u03b22, and\n\u03b25 subunits, which are responsible for its caspase-like, trypsin-like,\nand chymotrypsin-like (CT-like) activities, respectively. It is well\nestablished that inhibition of the \u03b25 proteasomal subunit is\nprimarily associated with apoptosis induction in tumor cells. Proliferation and apoptosis pathways are tightly regulated in the\ncell by the UPS, and alterations in the UPS may result in cellular\ntransformation or other pathological conditions. As the proteasome\nis often found to be overactive in cancer cells making it more sensitive\nto proteasome inhibition than normal cells, the development of proteasome\nas novel anticancer drugs has been sought for some time.\n</p>", "clean_text": "The ubiquitin-proteasome system (UPS) plays an important role in a multitude of cellular processes including cell cycle progression, apoptosis, angiogenesis, DNA damage and repair, drug resistance, and differentiation. The 20S proteasome is a high molecular weight protease complex with a proteolytic core containing \u03b21, \u03b22, and \u03b25 subunits, which are responsible for its caspase-like, trypsin-like, and chymotrypsin-like (CT-like) activities, respectively. It is well established that inhibition of the \u03b25 proteasomal subunit is primarily associated with apoptosis induction in tumor cells. Proliferation and apoptosis pathways are tightly regulated in the cell by the UPS, and alterations in the UPS may result in cellular transformation or other pathological conditions. As the proteasome is often found to be overactive in cancer cells making it more sensitive to proteasome inhibition than normal cells, the development of proteasome as novel anticancer drugs has been sought for some time. ", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 3, "type": "text", "classification": ["else"], "content": "<p>Most proteasome inhibitors are short peptides\nthat mimic protein\nsubstrates. Bortezomib and carfilzomib,\napproved by the US Food and Drug Administration, have proven to be\neffective therapeutic agents for multiple myeloma and mantle cell\nlymphoma. However, these drugs have not been successful in treating patients\nwith solid cancers, probably due to poor <italic>in vivo</italic> stability,\nundesirable pharmacokinetic properties, and unwanted toxicities arising\nfrom peptide backbones and electrophilic pharmacophores. Thus, there is an urgent need to generate new molecules that can\ninhibit the proteasome utilizing a nonpeptide scaffold which could\novercome these drawbacks.</p>", "clean_text": "Most proteasome inhibitors are short peptides that mimic protein substrates. Bortezomib and carfilzomib, approved by the US Food and Drug Administration, have proven to be effective therapeutic agents for multiple myeloma and mantle cell lymphoma. However, these drugs have not been successful in treating patients with solid cancers, probably due to poor in vivo stability, undesirable pharmacokinetic properties, and unwanted toxicities arising from peptide backbones and electrophilic pharmacophores. Thus, there is an urgent need to generate new molecules that can inhibit the proteasome utilizing a nonpeptide scaffold which could overcome these drawbacks.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 4, "type": "text", "classification": ["else"], "content": "<p>Metal-containing drugs have existed\nfor decades, and cisplatin,\na platinum containing compound, is known as one of the most effective\nantitumor drugs. Nowadays, the platinum drugs are still in the front\nline of metal-based cancer chemotherapy. However, their negative side-effects and the risk of resistance\nremain a pressing matter in their clinical use. These issues drive\nthe research and development of new metallotherapeutics, in many cases\ndivergent from the platinum metals-based complexes. Copper is biocompatible and less toxic than nonendogenous\nheavy metals. This makes it an interesting candidate for the treatment\nof cancers due to its bioavailability and the observation of increased\ncopper levels in cancer tissue. Therefore,\ncopper complexes are regarded as one of the most promising alternatives\nto cisplatin as anticancer substances. Copper complexes called Casiopei\u0301nas have proved their significant\nanticancer activity in both preclinical <italic>in vitro</italic> and <italic>in vivo</italic> testing, and two of them have entered Phase I clinical\ntrials. J. Zuo et al. have reported two amino acid Schiff base-copper complexes\nwhich could inhibit the chymotrypsin-like activity of 20S proteasome,\ncause accumulation of proteasome target proteins bax and I\u03baB-\u03b1,\nand induce growth inhibition and apoptosis in MDA-MB-231, MCF-7, and\nPC-3 tumor cells. Z.Y. Zhang et al. have\nreported a <sc>l</sc>-Ornithine Schiff base-copper complex with proteasome-inhibitory\nactivities and induction of apoptosis in MDA-MB-231 and LNCaP cancer\ncells.</p>", "clean_text": "Metal-containing drugs have existed for decades, and cisplatin, a platinum containing compound, is known as one of the most effective antitumor drugs. Nowadays, the platinum drugs are still in the front line of metal-based cancer chemotherapy. However, their negative side-effects and the risk of resistance remain a pressing matter in their clinical use. These issues drive the research and development of new metallotherapeutics, in many cases divergent from the platinum metals-based complexes. Copper is biocompatible and less toxic than nonendogenous heavy metals. This makes it an interesting candidate for the treatment of cancers due to its bioavailability and the observation of increased copper levels in cancer tissue. Therefore, copper complexes are regarded as one of the most promising alternatives to cisplatin as anticancer substances. Copper complexes called Casiopei\u0301nas have proved their significant anticancer activity in both preclinical in vitro and in vivo testing, and two of them have entered Phase I clinical trials. J. Zuo et al. have reported two amino acid Schiff base-copper complexes which could inhibit the chymotrypsin-like activity of 20S proteasome, cause accumulation of proteasome target proteins bax and I\u03baB-\u03b1, and induce growth inhibition and apoptosis in MDA-MB-231, MCF-7, and PC-3 tumor cells. Z.Y. Zhang et al. have reported a l-Ornithine Schiff base-copper complex with proteasome-inhibitory activities and induction of apoptosis in MDA-MB-231 and LNCaP cancer cells.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 5, "type": "text", "classification": "error", "content": "<p>Previously, we have reported some polypyridine-copper\ncomplexes\nas antitumor agents. These copper complexes are toxic to HeLa and MCF-7\ncells, with IC<sub>50</sub> values in the range of 6.70\u201316.58\n\u03bcM, inducing apoptosis in human cancer cells and inhibiting\ntumor cell growth, although their molecular mechanisms remain to be\nestablished. In order to improve the targeting and solubility of this\ntype of complex, we introduced an amino acid and generated five novel\namino-polypyridine-copper complexes. We found that they inhibit the\nproteasomal chymotrypsin-like activity, cause accumulation of ubiquitinated\nproteins, and induce growth inhibition and apoptosis in dose-dependent\nmanners. They also decrease the stemness of triple negative breast\ncancer (TNBC) cells, indicating their great potential as a novel therapy\nfor triple-negative breast cancer.</p>", "clean_text": "Previously, we have reported some polypyridine-copper complexes as antitumor agents. These copper complexes are toxic to HeLa and MCF-7 cells, with IC50 values in the range of 6.70-16.58 \u03bcM, inducing apoptosis in human cancer cells and inhibiting tumor cell growth, although their molecular mechanisms remain to be established. In order to improve the targeting and solubility of this type of complex, we introduced an amino acid and generated five novel amino-polypyridine-copper complexes. We found that they inhibit the proteasomal chymotrypsin-like activity, cause accumulation of ubiquitinated proteins, and induce growth inhibition and apoptosis in dose-dependent manners. They also decrease the stemness of triple negative breast cancer (TNBC) cells, indicating their great potential as a novel therapy for triple-negative breast cancer.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else]"}}, {"idx": 6, "type": "text", "classification": ["else"], "content": "<p>The synthesis and characterizations\nof complexes <bold>1</bold>\u2013<bold>5</bold> are described in\nthe <ext-link xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00284/suppl_file/ml9b00284_si_001.pdf\">Supporting Information</ext-link>. They have been structurally characterized by X-ray\ncrystallography (). The crystallographic data and structure refinement parameters\nfor the complexes <bold>1</bold>\u2013<bold>5</bold> are seen in <ext-link xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00284/suppl_file/ml9b00284_si_001.pdf\">Tables 1S and 2S</ext-link>.</p>", "clean_text": "The synthesis and characterizations of complexes 1-5 are described in the Supporting Information. They have been structurally characterized by X-ray crystallography (). The crystallographic data and structure refinement parameters for the complexes 1-5 are seen in Tables 1S and 2S.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 7, "type": "figure", "classification": null, "content": "<fig fig-type=\"figure\" id=\"fig1\" position=\"float\">\n<label>1</label>\n<caption>\n<p>Molecular structures\nof complexes <bold>1</bold>\u2013<bold>5</bold>, dissociative small\nmolecules and nonessential H atoms.</p>\n</caption>\n<graphic id=\"gr1\" position=\"float\" xlink:href=\"ml9b00284_0001.tif\"></graphic>\n</fig>", "clean_text": " 1  Molecular structures of complexes 1-5, dissociative small molecules and nonessential H atoms.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 8, "type": "text", "classification": "error", "content": "<p>Complexes <bold>1</bold>\u2013<bold>5</bold> were evaluated for\ntheir antiproliferative activity against human breast tumor CAL-51,\nMDA-MB-231, and MCF-7 cells by using an MTT assay and comparing their\ncytotoxicity to carboplatin (CBP). IC<sub>50</sub> values for complexes <bold>1</bold>\u2013<bold>5</bold> were lower than those of the free\nligand and copper salt in all of the tested cells, which suggests\nthat the coordinated copper\u00ad(II) ion plays a major role in mediating\nthe potency of the complexes (). The complexes <bold>1</bold>\u2013<bold>5</bold> had lower IC<sub>50</sub> values than CBP against the three breast\ncancer cells, indicating that these novel complexes have stronger\ntoxicity than carboplatin, a platinum compound commonly used in the\nclinic. Complexes <bold>1</bold>\u2013<bold>5</bold> had extremely\nlow IC<sub>50</sub> levels on CAL-51 cells, with the order of the\ncytotoxicity being <bold>3</bold> &gt; <bold>5</bold> &gt; <bold>2</bold> &gt; <bold>1</bold> &gt; <bold>4</bold>, indicating that the configuration\nof the amino acid affects the activity of the complexes. As complexes <bold>3</bold> (IC<sub>50</sub> = 0.08 \u03bcM) and <bold>5</bold> (IC<sub>50</sub> = 0.27 \u03bcM) were the most potent, their biological\nactivity on TNBC CAL-51 and MDA-MB-231 cells was evaluated further.</p>", "clean_text": "Complexes 1-5 were evaluated for their antiproliferative activity against human breast tumor CAL-51, MDA-MB-231, and MCF-7 cells by using an MTT assay and comparing their cytotoxicity to carboplatin (CBP). IC50 values for complexes 1-5 were lower than those of the free ligand and copper salt in all of the tested cells, which suggests that the coordinated copper(II) ion plays a major role in mediating the potency of the complexes (). The complexes 1-5 had lower IC50 values than CBP against the three breast cancer cells, indicating that these novel complexes have stronger toxicity than carboplatin, a platinum compound commonly used in the clinic. Complexes 1-5 had extremely low IC50 levels on CAL-51 cells, with the order of the cytotoxicity being 3 > 5 > 2 > 1 > 4, indicating that the configuration of the amino acid affects the activity of the complexes. As complexes 3 (IC50 = 0.08 \u03bcM) and 5 (IC50 = 0.27 \u03bcM) were the most potent, their biological activity on TNBC CAL-51 and MDA-MB-231 cells was evaluated further.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else]"}}, {"idx": 9, "type": "table", "classification": null, "content": "<table-wrap id=\"tbl1\" position=\"float\">\n<label>1</label>\n<caption>\n<title>Anti-proliferative Effects of Complexes <bold>1\u20135</bold> against Various Breast Cancer Cells</title>\n</caption>\n<oasis:table colsep=\"0\" rowsep=\"0\">\n<oasis:tgroup cols=\"4\">\n<oasis:colspec align=\"left\" colname=\"col1\"></oasis:colspec>\n<oasis:colspec align=\"left\" colname=\"col2\"></oasis:colspec>\n<oasis:colspec align=\"left\" colname=\"col3\"></oasis:colspec>\n<oasis:colspec align=\"left\" colname=\"col4\"></oasis:colspec>\n<oasis:thead>\n<oasis:row>\n<oasis:entry align=\"center\"></oasis:entry>\n<oasis:entry align=\"center\" nameend=\"col4\" namest=\"col2\" rowsep=\"1\">IC<sub>50</sub> (\u03bcM)</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry align=\"center\">Complex</oasis:entry>\n<oasis:entry align=\"center\">CAL-51</oasis:entry>\n<oasis:entry align=\"center\">MDA-MB-231</oasis:entry>\n<oasis:entry align=\"center\">MCF-7</oasis:entry>\n</oasis:row>\n</oasis:thead>\n<oasis:tbody>\n<oasis:row>\n<oasis:entry>1</oasis:entry>\n<oasis:entry>0.52\u00a0\u00b1\u00a00.02</oasis:entry>\n<oasis:entry>18.89\u00a0\u00b1\u00a01.23</oasis:entry>\n<oasis:entry>30.88\u00a0\u00b1\u00a02.56</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>2</oasis:entry>\n<oasis:entry>0.37\u00a0\u00b1\u00a00.04</oasis:entry>\n<oasis:entry>10.98\u00a0\u00b1\u00a00.95</oasis:entry>\n<oasis:entry>25.59\u00a0\u00b1\u00a02.10</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>3</oasis:entry>\n<oasis:entry>0.08\u00a0\u00b1\u00a00.004</oasis:entry>\n<oasis:entry>8.35\u00a0\u00b1\u00a00.55</oasis:entry>\n<oasis:entry>17.08\u00a0\u00b1\u00a01.64</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>4</oasis:entry>\n<oasis:entry>0.69\u00a0\u00b1\u00a00.04</oasis:entry>\n<oasis:entry>4.92\u00a0\u00b1\u00a00.36</oasis:entry>\n<oasis:entry>18.99\u00a0\u00b1\u00a01.54</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>5</oasis:entry>\n<oasis:entry>0.27\u00a0\u00b1\u00a00.02</oasis:entry>\n<oasis:entry>9.33\u00a0\u00b1\u00a00.84</oasis:entry>\n<oasis:entry>20.32\u00a0\u00b1\u00a02.01</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>Copper\nsalt</oasis:entry>\n<oasis:entry>&gt;100</oasis:entry>\n<oasis:entry>&gt;100</oasis:entry>\n<oasis:entry>&gt;100</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>OH-PIP</oasis:entry>\n<oasis:entry>18.51\u00a0\u00b1\u00a01.5</oasis:entry>\n<oasis:entry>22.84\u00a0\u00b1\u00a02.1</oasis:entry>\n<oasis:entry>68.08\u00a0\u00b1\u00a03.2</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>Carboplatin</oasis:entry>\n<oasis:entry>1.05\u00a0\u00b1\u00a00.1</oasis:entry>\n<oasis:entry>15.02\u00a0\u00b1\u00a01.4</oasis:entry>\n<oasis:entry>36.65\u00a0\u00b1\u00a02.5</oasis:entry>\n</oasis:row>\n</oasis:tbody>\n</oasis:tgroup>\n</oasis:table>\n</table-wrap>", "clean_text": "", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 10, "type": "text", "classification": "error", "content": "<p>To determine whether complexes <bold>3</bold> and <bold>5</bold> have synergistic effects with CBP on TNBC cells, MDA-MB-231\nand\nCAL-51 cells were treated with 3 \u03bcM CBP and different concentrations\nof either complex <bold>3</bold> or <bold>5</bold> for 48 h, and the\nproliferation was assessed by MTT assay. MDA-MB-231 cells treated\nwith 0.39\u201325.0 \u03bcM <bold>3</bold> and 0.19\u201312.5\n\u03bcM <bold>5</bold> showed CI values in the range 0.50\u20130.93\nand 0.03\u20130.92, respectively. Similarly, CAL-51 cells treated\nwith 0.19\u20136.25 \u03bcM <bold>3</bold> and 0.19\u20136.25\n\u03bcM <bold>5</bold> showed CI values in the range of 0.37\u20130.96\nand 0.43\u20130.86, respectively. In all cases CI values were lower\nthan 1.0 (<ext-link xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00284/suppl_file/ml9b00284_si_001.pdf\">Tables 3S and 4S</ext-link>), indicating\nsynergistic effects between the novel copper compounds and CBP on\nbreast cancer cells.</p>", "clean_text": "To determine whether complexes 3 and 5 have synergistic effects with CBP on TNBC cells, MDA-MB-231 and CAL-51 cells were treated with 3 \u03bcM CBP and different concentrations of either complex 3 or 5 for 48 h, and the proliferation was assessed by MTT assay. MDA-MB-231 cells treated with 0.39-25.0 \u03bcM 3 and 0.19-12.5 \u03bcM 5 showed CI values in the range 0.50-0.93 and 0.03-0.92, respectively. Similarly, CAL-51 cells treated with 0.19-6.25 \u03bcM 3 and 0.19-6.25 \u03bcM 5 showed CI values in the range of 0.37-0.96 and 0.43-0.86, respectively. In all cases CI values were lower than 1.0 (Tables 3S and 4S), indicating synergistic effects between the novel copper compounds and CBP on breast cancer cells.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else]"}}, {"idx": 11, "type": "text", "classification": ["else"], "content": "<p>To investigate whether the growth-inhibitory\nactivity of the complexes <bold>1</bold>\u2013<bold>5</bold> was\nassociated with their ability\nto inhibit the proteasome activity, purified human 20S proteasome\nwas treated with a range of compound concentrations for 2 h at 37\n\u00b0C in the presence of fluorogenic Suc-LLVY-AMC, a specific substrate\nfor the CT-like activity. The results indicate that these copper complexes\ndid inhibit the proteasomal CT-like activity in a dose-dependent manner\nand more efficiently than either the free ligand or copper salt (). Thus, complexes <bold>1</bold>\u2013<bold>5</bold> target the 20S proteasomal catalytic\n\u03b25 subunit.</p>", "clean_text": "To investigate whether the growth-inhibitory activity of the complexes 1-5 was associated with their ability to inhibit the proteasome activity, purified human 20S proteasome was treated with a range of compound concentrations for 2 h at 37 \u00b0C in the presence of fluorogenic Suc-LLVY-AMC, a specific substrate for the CT-like activity. The results indicate that these copper complexes did inhibit the proteasomal CT-like activity in a dose-dependent manner and more efficiently than either the free ligand or copper salt (). Thus, complexes 1-5 target the 20S proteasomal catalytic \u03b25 subunit.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 12, "type": "figure", "classification": null, "content": "<fig fig-type=\"figure\" id=\"fig2\" position=\"float\">\n<label>2</label>\n<caption>\n<p>Copper complexes inhibit proteasomal CT-like activity <italic>in\nvitro.</italic> Purified 20S proteasome was incubated in the presence\nof increasing concentration of copper salt, ligand, and copper complexes <bold>1</bold>\u2013<bold>5</bold> and the CT-like activity measured\nby the production of fluorescent AMC groups from Suc-LLVY-AMC substrate.\nData represent the average \u00b1 SD of three independent experiments.</p>\n</caption>\n<graphic id=\"gr2\" position=\"float\" xlink:href=\"ml9b00284_0002.tif\"></graphic>\n</fig>", "clean_text": " 2  Copper complexes inhibit proteasomal CT-like activity in vitro. Purified 20S proteasome was incubated in the presence of increasing concentration of copper salt, ligand, and copper complexes 1-5 and the CT-like activity measured by the production of fluorescent AMC groups from Suc-LLVY-AMC substrate. Data represent the average \u00b1 SD of three independent experiments.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 13, "type": "text", "classification": ["else"], "content": "<p>In order to ascertain that proteasome inhibition\nby the copper\ncomplexes is associated with apoptosis induction, cellular morphological\nchanges were monitored in MDA-MB-231 and CAL-51 cells after 24 h treatment.\nCells treated with complexes <bold>3</bold> and <bold>5</bold> at\na concentration double their IC<sub>50</sub> appeared with characteristic\ndose-dependent apoptotic blebbing (<ext-link xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00284/suppl_file/ml9b00284_si_001.pdf\">Figures 1S</ext-link>). These results suggest that complexes <bold>3</bold> and <bold>5</bold> have the ability to inhibit the proteasome and induce apoptosis\nin a concentration-dependent manner in MDA-MB-231 and CAL-51 cells.</p>", "clean_text": "In order to ascertain that proteasome inhibition by the copper complexes is associated with apoptosis induction, cellular morphological changes were monitored in MDA-MB-231 and CAL-51 cells after 24 h treatment. Cells treated with complexes 3 and 5 at a concentration double their IC50 appeared with characteristic dose-dependent apoptotic blebbing (Figures 1S). These results suggest that complexes 3 and 5 have the ability to inhibit the proteasome and induce apoptosis in a concentration-dependent manner in MDA-MB-231 and CAL-51 cells.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 14, "type": "text", "classification": "error", "content": "<p>To elucidate the mechanism by which copper complexes cause cell\ndeath in human tumor cells, we performed apoptotic assays by Annexin\nV-propidium iodide staining in cells after 24 h treatment with the\ncomplexes at 1\u00d7 and 2\u00d7 their IC<sub>50</sub>. In MDA-MB-231\ncells, complex <bold>3</bold> at 8.35 and 16.70 \u03bcM triggered\ncell death in a dose-dependent manner, with total apoptotic values\nof 7.5% and 56.9%, respectively. In a similar fashion, the apoptotic\nvalues of complex <bold>5</bold> at 9.33 and 18.66 \u03bcM were 56.5%\nand 74.5%, respectively. Importantly, most of the cell death reported\nwas due to cells in early apoptosis (). CAL-51 cells responded in the same way:\ncomplex <bold>3</bold> at 0.082 and 0.16 \u03bcM triggered cell death\nin a dose-dependent manner, with total apoptotic values of 8.6% and\n15.5%, respectively, whereas the apoptotic values after treatment\nwith complex <bold>5</bold> at 0.27 and 0.54 \u03bcM were 10.5% and\n14.4%, respectively (). Although <bold>3</bold> and <bold>5</bold> induced apoptosis\nmore efficiently in MDA-MB-231 than in CAL-51 cells, overall these\nresults indicate that both compounds induce apoptosis in a dose-dependent\nmanner in TNBC cells.</p>", "clean_text": "To elucidate the mechanism by which copper complexes cause cell death in human tumor cells, we performed apoptotic assays by Annexin V-propidium iodide staining in cells after 24 h treatment with the complexes at 1\u00d7 and 2\u00d7 their IC50. In MDA-MB-231 cells, complex 3 at 8.35 and 16.70 \u03bcM triggered cell death in a dose-dependent manner, with total apoptotic values of 7.5% and 56.9%, respectively. In a similar fashion, the apoptotic values of complex 5 at 9.33 and 18.66 \u03bcM were 56.5% and 74.5%, respectively. Importantly, most of the cell death reported was due to cells in early apoptosis (). CAL-51 cells responded in the same way: complex 3 at 0.082 and 0.16 \u03bcM triggered cell death in a dose-dependent manner, with total apoptotic values of 8.6% and 15.5%, respectively, whereas the apoptotic values after treatment with complex 5 at 0.27 and 0.54 \u03bcM were 10.5% and 14.4%, respectively (). Although 3 and 5 induced apoptosis more efficiently in MDA-MB-231 than in CAL-51 cells, overall these results indicate that both compounds induce apoptosis in a dose-dependent manner in TNBC cells.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else]"}}, {"idx": 15, "type": "figure", "classification": null, "content": "<fig fig-type=\"figure\" id=\"fig3\" position=\"float\">\n<label>3</label>\n<caption>\n<p>Copper complexes induce apoptosis in TNBC MDA-MB-231 cells.\nCells\nwere treated with the copper complexes at 1 \u00d7 and 2 \u00d7 IC<sub>50</sub> concentrations for 24 h and apoptosis detected by flow cytometry\nusing annexin V (<italic>x</italic> axis)\u2013propidium iodide\n(<italic>y</italic> axis) staining. Early apoptotic cells (annexin\nV-positive, propidium iodide-negative) appear in the lower right quadrant\nand late apoptotic cells (positive for both markers) in the upper\nright quadrant. The percentage of cells in apoptotic quadrants is\nshown. Cytometry plots are representative of three independent experiments.\nHistogram indicates average apoptosis (both early and late) \u00b1\nSD from three independent experiments.</p>\n</caption>\n<graphic id=\"gr3\" position=\"float\" xlink:href=\"ml9b00284_0003.tif\"></graphic>\n</fig>", "clean_text": " 3  Copper complexes induce apoptosis in TNBC MDA-MB-231 cells. Cells were treated with the copper complexes at 1 \u00d7 and 2 \u00d7 IC50 concentrations for 24 h and apoptosis detected by flow cytometry using annexin V (x axis)-propidium iodide (y axis) staining. Early apoptotic cells (annexin V-positive, propidium iodide-negative) appear in the lower right quadrant and late apoptotic cells (positive for both markers) in the upper right quadrant. The percentage of cells in apoptotic quadrants is shown. Cytometry plots are representative of three independent experiments. Histogram indicates average apoptosis (both early and late) \u00b1 SD from three independent experiments.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 16, "type": "figure", "classification": null, "content": "<fig fig-type=\"figure\" id=\"fig4\" position=\"float\">\n<label>4</label>\n<caption>\n<p>Copper\ncomplexes induce apoptosis in TNBC CAL-51 cells. Cells were\ntreated with copper complexes at 1 \u00d7 and 2 \u00d7 IC<sub>50</sub> concentrations for 24 h and apoptosis detected by flow cytometry\nusing annexin V (<italic>x</italic> axis)\u2013propidium iodide\n(<italic>y</italic> axis) staining. Early apoptotic cells (annexin\nV-positive, propidium iodide-negative) appear in the lower right quadrant\nand late apoptotic cells (positive for both markers) in the upper\nright quadrant. Percentage of cells in apoptotic quadrants is shown.\nCytometry plots are representative of three independent experiments.\nHistogram indicates average apoptosis (both early and late) \u00b1\nSD from three independent experiments.</p>\n</caption>\n<graphic id=\"gr4\" position=\"float\" xlink:href=\"ml9b00284_0004.tif\"></graphic>\n</fig>", "clean_text": " 4  Copper complexes induce apoptosis in TNBC CAL-51 cells. Cells were treated with copper complexes at 1 \u00d7 and 2 \u00d7 IC50 concentrations for 24 h and apoptosis detected by flow cytometry using annexin V (x axis)-propidium iodide (y axis) staining. Early apoptotic cells (annexin V-positive, propidium iodide-negative) appear in the lower right quadrant and late apoptotic cells (positive for both markers) in the upper right quadrant. Percentage of cells in apoptotic quadrants is shown. Cytometry plots are representative of three independent experiments. Histogram indicates average apoptosis (both early and late) \u00b1 SD from three independent experiments.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 17, "type": "text", "classification": "error", "content": "<p>Key regulators of the apoptotic pathway include Bax, Bcl-2, and\nCaspase family proteins. When Bax expression is high, cells proceed\nto apoptosis, whereas when Bcl-2 is produced in excess, cells are\nprotected from apoptosis. In order to\nvalidate the functional results shown above and to gain insights into\nthe molecular mechanisms of cell death triggered by the copper complexes,\nwe used Western blots to detect Bax, Bcl-2, and caspase-3 protein\nexpression in MDA-MB-231 and CAL-51 cells treated with <bold>3</bold> and <bold>5</bold> at the IC<sub>50</sub> and 2 \u00d7 IC<sub>50</sub> for 24 h. Levels of Bax protein increased, while Bcl-2 and caspase-3\nprotein expression levels were downregulated, upon treatment with\nthe copper complexes (). Furthermore, the PARP cleavage fragment p89 appeared after\n24 h treatment, indicating that the cancer cells were undergoing apoptosis.\nIn addition, and consistent with the inhibition of proteasomal inhibiton\nunder cell-free conditions, increased levels of ubiquitinated proteins\nwere also detected in a dose-dependent fashion upon copper complexes\ntreatment. These cellular data further indicate that the complexes\ninhibit proteasome activity and induce apoptosis.</p>", "clean_text": "Key regulators of the apoptotic pathway include Bax, Bcl-2, and Caspase family proteins. When Bax expression is high, cells proceed to apoptosis, whereas when Bcl-2 is produced in excess, cells are protected from apoptosis. In order to validate the functional results shown above and to gain insights into the molecular mechanisms of cell death triggered by the copper complexes, we used Western blots to detect Bax, Bcl-2, and caspase-3 protein expression in MDA-MB-231 and CAL-51 cells treated with 3 and 5 at the IC50 and 2 \u00d7 IC50 for 24 h. Levels of Bax protein increased, while Bcl-2 and caspase-3 protein expression levels were downregulated, upon treatment with the copper complexes (). Furthermore, the PARP cleavage fragment p89 appeared after 24 h treatment, indicating that the cancer cells were undergoing apoptosis. In addition, and consistent with the inhibition of proteasomal inhibiton under cell-free conditions, increased levels of ubiquitinated proteins were also detected in a dose-dependent fashion upon copper complexes treatment. These cellular data further indicate that the complexes inhibit proteasome activity and induce apoptosis.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else]"}}, {"idx": 18, "type": "figure", "classification": null, "content": "<fig fig-type=\"figure\" id=\"fig5\" position=\"float\">\n<label>5</label>\n<caption>\n<p>Complexes <bold>3</bold> and <bold>5</bold> induce accumulation\nof ubiquitinated proteins and apoptosis. Breast cancer MDA-MB-231\nand CAL-51 cells were treated with <bold>3</bold> and <bold>5</bold> at 1 \u00d7 and 2 \u00d7 IC<sub>50</sub> concentrations for 24 h\nand ubiquitinated proteins, Caspase-3, PARP, Bcl-2, and Bax proteins\ndetected by Western blotting. Housekeeping GAPDH levels were used\nto confirm equal protein loading. Arrow indicates molecular mass in\nkDa. Band intensity was quantified using ImageJ and shown as the average\n\u00b1 SD (<italic>n</italic> = 3), *<italic>P</italic> &lt; 0.05.</p>\n</caption>\n<graphic id=\"gr5\" position=\"float\" xlink:href=\"ml9b00284_0005.tif\"></graphic>\n</fig>", "clean_text": " 5  Complexes 3 and 5 induce accumulation of ubiquitinated proteins and apoptosis. Breast cancer MDA-MB-231 and CAL-51 cells were treated with 3 and 5 at 1 \u00d7 and 2 \u00d7 IC50 concentrations for 24 h and ubiquitinated proteins, Caspase-3, PARP, Bcl-2, and Bax proteins detected by Western blotting. Housekeeping GAPDH levels were used to confirm equal protein loading. Arrow indicates molecular mass in kDa. Band intensity was quantified using ImageJ and shown as the average \u00b1 SD (n = 3), *P < 0.05.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 19, "type": "text", "classification": "error", "content": "<p>Cancer stem cells (CSCs), a subpopulation of tumor\ncells possessing\nthe extensive self-renewal capability necessary to successfully colonize\ndistant organs, relate to highly aggressive TNBC. The CD44<sup>+</sup>/CD24<sup>\u2013</sup> breast cancer\ncell subpopulation has a strong tumor forming ability, and these markers\nare considered one of the best in the field to determine breast CSC. In the treatment of breast cancer, the elimination of breast cancer\nstem cells is the key to completely cure the disease. To determine\nwhether <bold>3</bold> and <bold>5</bold> have the capacity to modulate\nstem cell phenotypes, we determined the extent of CD44<sup>+</sup>/CD24<sup>\u2013</sup> population by flow cytometry. Indeed, MDA-MB-231\ncells showed a dose-dependent decrease in CD44<sup>+</sup>/CD24<sup>\u2013</sup> stem cell population of 12.3% and 13.4% when treated\nwith 16.7 \u03bcM complex <bold>3</bold> and 18.66 \u03bcM complex <bold>5</bold>, respectively ( and <ext-link xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00284/suppl_file/ml9b00284_si_001.pdf\">Table 5S</ext-link>).</p>", "clean_text": "Cancer stem cells (CSCs), a subpopulation of tumor cells possessing the extensive self-renewal capability necessary to successfully colonize distant organs, relate to highly aggressive TNBC. The CD44+/CD24- breast cancer cell subpopulation has a strong tumor forming ability, and these markers are considered one of the best in the field to determine breast CSC. In the treatment of breast cancer, the elimination of breast cancer stem cells is the key to completely cure the disease. To determine whether 3 and 5 have the capacity to modulate stem cell phenotypes, we determined the extent of CD44+/CD24- population by flow cytometry. Indeed, MDA-MB-231 cells showed a dose-dependent decrease in CD44+/CD24- stem cell population of 12.3% and 13.4% when treated with 16.7 \u03bcM complex 3 and 18.66 \u03bcM complex 5, respectively ( and Table 5S).", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else]"}}, {"idx": 20, "type": "figure", "classification": null, "content": "<fig fig-type=\"figure\" id=\"fig6\" position=\"float\">\n<label>6</label>\n<caption>\n<p>Complexes <bold>3</bold> and <bold>5</bold> decrease stem cell\nmarkers in MDA-MB-231 cells. Breast cancer MDA-MB-231 cells were treated\nwith <bold>3</bold> and <bold>5</bold> at 0.5 \u00d7, 1 \u00d7, and\n2 \u00d7 IC<sub>50</sub> concentrations for 24 h, and the percentage\nof the CD44<sup>+</sup>/CD24<sup>\u2013</sup> cell subpopulation\nwas determined by flow cytometry. Histogram indicates the average\npercentage of the CD44<sup>+</sup>/CD24<sup>\u2013</sup> cell subpopulation\nfrom three independent experiments.</p>\n</caption>\n<graphic id=\"gr6\" position=\"float\" xlink:href=\"ml9b00284_0006.tif\"></graphic>\n</fig>", "clean_text": " 6  Complexes 3 and 5 decrease stem cell markers in MDA-MB-231 cells. Breast cancer MDA-MB-231 cells were treated with 3 and 5 at 0.5 \u00d7, 1 \u00d7, and 2 \u00d7 IC50 concentrations for 24 h, and the percentage of the CD44+/CD24- cell subpopulation was determined by flow cytometry. Histogram indicates the average percentage of the CD44+/CD24- cell subpopulation from three independent experiments.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 21, "type": "text", "classification": "error", "content": "<p>As ALDH has also been identified as a CSC marker in different types\nof cancers and represents the CSC subpopulation better than CD44<sup>+</sup>/CD24<sup>\u2013</sup> in CAL-51 cells, we also tested ALDH activity by ALDEFLUOR assay in both\ncell lines. Both complexes <bold>3</bold> and <bold>5</bold> reduced\nthe percentage of ALDH-positive cells in a dose-dependent manner.\nIn MDA-MB-231 cells, that show 22.7% ALDH-positive cells, complex <bold>3</bold> treatment at 16.7 \u03bcM reduced them to 0.72%, whereas\ntreatment with <bold>5</bold> at 18.6 \u03bcM reduced them to 1.02%\n(). Similarly,\nCAL-51 cells, with 45.5% ALDH-positive cells, when treated with complex <bold>3</bold> had a reduction in the percentage of ALDH-positive cells\nto 8.25% and when treated with complex <bold>5</bold> had a reduction\nto 5.50% ( and <ext-link xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00284/suppl_file/ml9b00284_si_001.pdf\">Table 6S</ext-link>).</p>", "clean_text": "As ALDH has also been identified as a CSC marker in different types of cancers and represents the CSC subpopulation better than CD44+/CD24- in CAL-51 cells, we also tested ALDH activity by ALDEFLUOR assay in both cell lines. Both complexes 3 and 5 reduced the percentage of ALDH-positive cells in a dose-dependent manner. In MDA-MB-231 cells, that show 22.7% ALDH-positive cells, complex 3 treatment at 16.7 \u03bcM reduced them to 0.72%, whereas treatment with 5 at 18.6 \u03bcM reduced them to 1.02% (). Similarly, CAL-51 cells, with 45.5% ALDH-positive cells, when treated with complex 3 had a reduction in the percentage of ALDH-positive cells to 8.25% and when treated with complex 5 had a reduction to 5.50% ( and Table 6S).", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else]"}}, {"idx": 22, "type": "figure", "classification": null, "content": "<fig fig-type=\"figure\" id=\"fig7\" position=\"float\">\n<label>7</label>\n<caption>\n<p>Complexes <bold>3</bold> and <bold>5</bold> decrease stem cell\nmarker ALDH in MDA-MB-231 cells. Breast cancer MDA-MB-231 cells were\ntreated with <bold>3</bold> and <bold>5</bold> at 0.5 \u00d7 , 1 \u00d7,\nand 2 \u00d7 IC<sub>50</sub> concentrations for 24 h and the percentage\nof ALDH<sup>+</sup> cells determined by flow cytometry. In order to\nbetter visualize ALDH<sup>+</sup> cells, two-dimensional plots were\nobtained. SSC, side scatter channel. Histogram indicates the average\npercentage of the ALDH<sup>+</sup> cell subpopulation from three independent\nexperiments.</p>\n</caption>\n<graphic id=\"gr7\" position=\"float\" xlink:href=\"ml9b00284_0007.tif\"></graphic>\n</fig>", "clean_text": " 7  Complexes 3 and 5 decrease stem cell marker ALDH in MDA-MB-231 cells. Breast cancer MDA-MB-231 cells were treated with 3 and 5 at 0.5 \u00d7 , 1 \u00d7, and 2 \u00d7 IC50 concentrations for 24 h and the percentage of ALDH+ cells determined by flow cytometry. In order to better visualize ALDH+ cells, two-dimensional plots were obtained. SSC, side scatter channel. Histogram indicates the average percentage of the ALDH+ cell subpopulation from three independent experiments.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 23, "type": "figure", "classification": null, "content": "<fig fig-type=\"figure\" id=\"fig8\" position=\"float\">\n<label>8</label>\n<caption>\n<p>Complexes <bold>3</bold> and <bold>5</bold> decrease\nstem cell\nmarker ALDH in CAL-51 cells. Breast cancer CAL-51 cells were treated\nwith <bold>3</bold> and <bold>5</bold> at 0.5 \u00d7 , 1 \u00d7, and\n2 \u00d7 IC<sub>50</sub> concentrations for 24 h and the percentage\nof ALDH<sup>+</sup> cells determined by flow cytometry. In order to\nbetter visualize ALDH<sup>+</sup> cells, two-dimensional plots were\nobtained. SSC, side scatter channel. Histogram indicates the average\npercentage of the ALDH<sup>+</sup> cell subpopulation from three independent\nexperiments.</p>\n</caption>\n<graphic id=\"gr8\" position=\"float\" xlink:href=\"ml9b00284_0008.tif\"></graphic>\n</fig>", "clean_text": " 8  Complexes 3 and 5 decrease stem cell marker ALDH in CAL-51 cells. Breast cancer CAL-51 cells were treated with 3 and 5 at 0.5 \u00d7 , 1 \u00d7, and 2 \u00d7 IC50 concentrations for 24 h and the percentage of ALDH+ cells determined by flow cytometry. In order to better visualize ALDH+ cells, two-dimensional plots were obtained. SSC, side scatter channel. Histogram indicates the average percentage of the ALDH+ cell subpopulation from three independent experiments.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 24, "type": "text", "classification": ["else"], "content": "<p>Although CSC marker studies are\ninformative, tumorsphere assays\nwere carried out to investigate whether <bold>3</bold> and <bold>5</bold> did affect tumor forming characteristics <italic>in vitro</italic> and how they compared to CBP. Seen in <ext-link xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00284/suppl_file/ml9b00284_si_001.pdf\">Figure 2S</ext-link>, compared with control, both TNBC cell lines produced robust\ntumorspheres that decreased in size after CBP treatment. However, <bold>3</bold> and <bold>5</bold> completely disaggregated the spheres\nand, at the highest dose, led to their depletion. Thus, both <bold>3</bold> and <bold>5</bold> decrease the stemness of TNBC cells.</p>", "clean_text": "Although CSC marker studies are informative, tumorsphere assays were carried out to investigate whether 3 and 5 did affect tumor forming characteristics in vitro and how they compared to CBP. Seen in Figure 2S, compared with control, both TNBC cell lines produced robust tumorspheres that decreased in size after CBP treatment. However, 3 and 5 completely disaggregated the spheres and, at the highest dose, led to their depletion. Thus, both 3 and 5 decrease the stemness of TNBC cells.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 25, "type": "text", "classification": "error", "content": "<p>The docking analysis provided new insights on a possible mechanism\nof proteasome inhibition. The molecular modeling results may account\nfor the data observed in the purified proteasome studies. As shown\nin , in addition\nto forming a hydrophobic interaction with the hydrophobic pocket composed\nof residues Ala-50, Ala-49, Ala-46, Met-45, Ala-31, Ala-20, Ala-22,\nand Ala-27, complex <bold>1</bold> formed hydrogen bonding through\nhydroxyl interaction with residue Ala-93, and formed hydrogen bonding\nthrough imidazole-NH with residue Gly-94, and formed hydrogen bonding\nthrough amino acid with residue Gly-47 and Ala-49; complex <bold>2</bold> formed hydrogen bonding through hydroxyl interaction with residue\nLys-32, and formed hydrogen bonding through imidazole with residue\nAla-49 and Thr-1, and formed hydrogen bonding through amino acid with\nresidue Gly-23; complex <bold>3</bold> formed hydrogen bonding through\namino acid with residue Thr-1, and formed a coordination bond between\ncopper atom and residue Gly-47; complex <bold>4</bold> formed hydrogen\nbonding through imidazole-NH with residue Thr-1, and formed hydrogen\nbonding through amino acid with residue Lys-23, and formed hydrogen\nbonding through oxygen atom with residue Gln-53; complex <bold>5</bold> formed hydrogen bonding through amino acid with residues Thr-1 and\nSer-129, and formed a coordination bond between copper atom and residue\nGly-47. The minimum relative binding energy values were \u22127.51,\n\u22127.82, \u22126.51, \u22126.49, and \u22126.04 kcal/mol\nfor <bold>1</bold>\u2013<bold>5</bold>, respectively, indicating\nthe interaction between the copper complexes and 20S proteasome.</p>", "clean_text": "The docking analysis provided new insights on a possible mechanism of proteasome inhibition. The molecular modeling results may account for the data observed in the purified proteasome studies. As shown in , in addition to forming a hydrophobic interaction with the hydrophobic pocket composed of residues Ala-50, Ala-49, Ala-46, Met-45, Ala-31, Ala-20, Ala-22, and Ala-27, complex 1 formed hydrogen bonding through hydroxyl interaction with residue Ala-93, and formed hydrogen bonding through imidazole-NH with residue Gly-94, and formed hydrogen bonding through amino acid with residue Gly-47 and Ala-49; complex 2 formed hydrogen bonding through hydroxyl interaction with residue Lys-32, and formed hydrogen bonding through imidazole with residue Ala-49 and Thr-1, and formed hydrogen bonding through amino acid with residue Gly-23; complex 3 formed hydrogen bonding through amino acid with residue Thr-1, and formed a coordination bond between copper atom and residue Gly-47; complex 4 formed hydrogen bonding through imidazole-NH with residue Thr-1, and formed hydrogen bonding through amino acid with residue Lys-23, and formed hydrogen bonding through oxygen atom with residue Gln-53; complex 5 formed hydrogen bonding through amino acid with residues Thr-1 and Ser-129, and formed a coordination bond between copper atom and residue Gly-47. The minimum relative binding energy values were -7.51, -7.82, -6.51, -6.49, and -6.04 kcal/mol for 1-5, respectively, indicating the interaction between the copper complexes and 20S proteasome.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else]"}}, {"idx": 26, "type": "figure", "classification": null, "content": "<fig fig-type=\"figure\" id=\"fig9\" position=\"float\">\n<label>9</label>\n<caption>\n<p>Schematic\nrepresentation of the proposed binding modes for complexes <bold>1</bold>\u2013<bold>5</bold> with proteasome (PDB ID:<ext-link ext-link-type=\"pdb\" xlink:href=\"3MG6\">3MG6</ext-link>). Only amino acids\nlocated within 4 \u00c5 of the bound ligand are displayed and labeled.\nKey H-bonds between the complexes and the protein are shown as dashed\nyellow lines.</p>\n</caption>\n<graphic id=\"gr9\" position=\"float\" xlink:href=\"ml9b00284_0009.tif\"></graphic>\n</fig>", "clean_text": " 9  Schematic representation of the proposed binding modes for complexes 1-5 with proteasome (PDB ID:3MG6). Only amino acids located within 4 \u00c5 of the bound ligand are displayed and labeled. Key H-bonds between the complexes and the protein are shown as dashed yellow lines.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 27, "type": "text", "classification": ["else"], "content": "<p>The Supporting\nInformation is\navailable free of charge on the <ext-link xlink:href=\"http://pubs.acs.org\">ACS Publications website</ext-link> at DOI: <ext-link xlink:href=\"http://pubs.acs.org/doi/abs/10.1021/acsmedchemlett.9b00284\">10.1021/acsmedchemlett.9b00284</ext-link>.<list id=\"silist\" list-type=\"label\">\n<list-item>\n<p>Crystallographic data and structure\nrefinement parameters,\nselected bond lengths (\u00c5) and angles (deg) for complexes <bold>1</bold>\u2013<bold>5</bold>. The CI values of combination of <bold>3</bold> or <bold>5</bold> and CBP for MDA-MB-231 and CAL-51 cells.\nThe effects of <bold>3</bold> and <bold>5</bold> on CD44<sup>+</sup>/CD24<sup>\u2013</sup> phenotype cell subsets in MDA-MB-231 were\ndetected by flow cytometry. The effects of <bold>3</bold> and <bold>5</bold> on the ratio of ALDH1+ cell population in MDA-MB-231 and\nCAL-51 was detected by flow cytometry. <bold>3</bold> and <bold>5</bold> abolish the tumor forming capacity of TNBC cells <italic>in vitro</italic>. (<ext-link xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00284/suppl_file/ml9b00284_si_001.pdf\">PDF</ext-link>)</p>\n</list-item>\n</list>\n</p>", "clean_text": "The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acsmedchemlett.9b00284.  Crystallographic data and structure refinement parameters, selected bond lengths (\u00c5) and angles (deg) for complexes 1-5. The CI values of combination of 3 or 5 and CBP for MDA-MB-231 and CAL-51 cells. The effects of 3 and 5 on CD44+/CD24- phenotype cell subsets in MDA-MB-231 were detected by flow cytometry. The effects of 3 and 5 on the ratio of ALDH1+ cell population in MDA-MB-231 and CAL-51 was detected by flow cytometry. 3 and 5 abolish the tumor forming capacity of TNBC cells in vitro. (PDF)   ", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 28, "type": "text", "classification": ["else"], "content": "<p>Crystallographic data and structure\nrefinement parameters,\nselected bond lengths (\u00c5) and angles (deg) for complexes <bold>1</bold>\u2013<bold>5</bold>. The CI values of combination of <bold>3</bold> or <bold>5</bold> and CBP for MDA-MB-231 and CAL-51 cells.\nThe effects of <bold>3</bold> and <bold>5</bold> on CD44<sup>+</sup>/CD24<sup>\u2013</sup> phenotype cell subsets in MDA-MB-231 were\ndetected by flow cytometry. The effects of <bold>3</bold> and <bold>5</bold> on the ratio of ALDH1+ cell population in MDA-MB-231 and\nCAL-51 was detected by flow cytometry. <bold>3</bold> and <bold>5</bold> abolish the tumor forming capacity of TNBC cells <italic>in vitro</italic>. (<ext-link xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00284/suppl_file/ml9b00284_si_001.pdf\">PDF</ext-link>)</p>", "clean_text": "Crystallographic data and structure refinement parameters, selected bond lengths (\u00c5) and angles (deg) for complexes 1-5. The CI values of combination of 3 or 5 and CBP for MDA-MB-231 and CAL-51 cells. The effects of 3 and 5 on CD44+/CD24- phenotype cell subsets in MDA-MB-231 were detected by flow cytometry. The effects of 3 and 5 on the ratio of ALDH1+ cell population in MDA-MB-231 and CAL-51 was detected by flow cytometry. 3 and 5 abolish the tumor forming capacity of TNBC cells in vitro. (PDF)", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 29, "type": "text", "classification": ["else"], "content": "<p>The manuscript\nwas written through contributions of all authors</p><p>This work was\nsupported by the National Natural Science Foundation of China (21501134).</p><p>The authors declare no\ncompeting financial interest.</p><title>Abbreviations</title><p>Human breast cancer cell line</p><p>Human breast\ncancer cell line</p><p>Human breast cancer cell line</p><p>triple-negative breast cancer</p><p>Carboplatin</p><p>Cancer stem cells</p>", "clean_text": "The manuscript was written through contributions of all authors\n\nThis work was supported by the National Natural Science Foundation of China (21501134).\n\nThe authors declare no competing financial interest.\n\nAbbreviations\n\nHuman breast cancer cell line\n\nHuman breast cancer cell line\n\nHuman breast cancer cell line\n\ntriple-negative breast cancer\n\nCarboplatin\n\nCancer stem cells", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}], "cln_elements": [{"idx": 9, "type": "table", "classification": ["Property"], "content": "<table-wrap id=\"tbl1\" position=\"float\">\n<label>1</label>\n<caption>\n<title>Anti-proliferative Effects of Complexes <bold>1\u20135</bold> against Various Breast Cancer Cells</title>\n</caption>\n<oasis:table colsep=\"0\" rowsep=\"0\">\n<oasis:tgroup cols=\"4\">\n<oasis:colspec align=\"left\" colname=\"col1\"></oasis:colspec>\n<oasis:colspec align=\"left\" colname=\"col2\"></oasis:colspec>\n<oasis:colspec align=\"left\" colname=\"col3\"></oasis:colspec>\n<oasis:colspec align=\"left\" colname=\"col4\"></oasis:colspec>\n<oasis:thead>\n<oasis:row>\n<oasis:entry align=\"center\"></oasis:entry>\n<oasis:entry align=\"center\" nameend=\"col4\" namest=\"col2\" rowsep=\"1\">IC<sub>50</sub> (\u03bcM)</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry align=\"center\">Complex</oasis:entry>\n<oasis:entry align=\"center\">CAL-51</oasis:entry>\n<oasis:entry align=\"center\">MDA-MB-231</oasis:entry>\n<oasis:entry align=\"center\">MCF-7</oasis:entry>\n</oasis:row>\n</oasis:thead>\n<oasis:tbody>\n<oasis:row>\n<oasis:entry>1</oasis:entry>\n<oasis:entry>0.52\u00a0\u00b1\u00a00.02</oasis:entry>\n<oasis:entry>18.89\u00a0\u00b1\u00a01.23</oasis:entry>\n<oasis:entry>30.88\u00a0\u00b1\u00a02.56</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>2</oasis:entry>\n<oasis:entry>0.37\u00a0\u00b1\u00a00.04</oasis:entry>\n<oasis:entry>10.98\u00a0\u00b1\u00a00.95</oasis:entry>\n<oasis:entry>25.59\u00a0\u00b1\u00a02.10</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>3</oasis:entry>\n<oasis:entry>0.08\u00a0\u00b1\u00a00.004</oasis:entry>\n<oasis:entry>8.35\u00a0\u00b1\u00a00.55</oasis:entry>\n<oasis:entry>17.08\u00a0\u00b1\u00a01.64</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>4</oasis:entry>\n<oasis:entry>0.69\u00a0\u00b1\u00a00.04</oasis:entry>\n<oasis:entry>4.92\u00a0\u00b1\u00a00.36</oasis:entry>\n<oasis:entry>18.99\u00a0\u00b1\u00a01.54</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>5</oasis:entry>\n<oasis:entry>0.27\u00a0\u00b1\u00a00.02</oasis:entry>\n<oasis:entry>9.33\u00a0\u00b1\u00a00.84</oasis:entry>\n<oasis:entry>20.32\u00a0\u00b1\u00a02.01</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>Copper\nsalt</oasis:entry>\n<oasis:entry>&gt;100</oasis:entry>\n<oasis:entry>&gt;100</oasis:entry>\n<oasis:entry>&gt;100</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>OH-PIP</oasis:entry>\n<oasis:entry>18.51\u00a0\u00b1\u00a01.5</oasis:entry>\n<oasis:entry>22.84\u00a0\u00b1\u00a02.1</oasis:entry>\n<oasis:entry>68.08\u00a0\u00b1\u00a03.2</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>Carboplatin</oasis:entry>\n<oasis:entry>1.05\u00a0\u00b1\u00a00.1</oasis:entry>\n<oasis:entry>15.02\u00a0\u00b1\u00a01.4</oasis:entry>\n<oasis:entry>36.65\u00a0\u00b1\u00a02.5</oasis:entry>\n</oasis:row>\n</oasis:tbody>\n</oasis:tgroup>\n</oasis:table>\n</table-wrap>", "clean_text": "Table 1. Anti-proliferative Effects of Complexes 1\u20135 against Various Breast Cancer Cells\n\n| Complex | CAL-51     | MDA-MB-231 | MCF-7      |\n|---------|------------|------------|------------|\n| 1       | 0.52\u00a0\u00b1\u00a00.02 | 18.89\u00a0\u00b1\u00a01.23 | 30.88\u00a0\u00b1\u00a02.56 |\n| 2       | 0.37\u00a0\u00b1\u00a00.04 | 10.98\u00a0\u00b1\u00a00.95 | 25.59\u00a0\u00b1\u00a02.10 |\n| 3       | 0.08\u00a0\u00b1\u00a00.004 | 8.35\u00a0\u00b1\u00a00.55 | 17.08\u00a0\u00b1\u00a01.64 |\n| 4       | 0.69\u00a0\u00b1\u00a00.04 | 4.92\u00a0\u00b1\u00a00.36 | 18.99\u00a0\u00b1\u00a01.54 |\n| 5       | 0.27\u00a0\u00b1\u00a00.02 | 9.33\u00a0\u00b1\u00a00.84 | 20.32\u00a0\u00b1\u00a02.01 |\n| Copper salt | >100 | >100 | >100 |\n| OH-PIP  | 18.51\u00a0\u00b1\u00a01.5 | 22.84\u00a0\u00b1\u00a02.1 | 68.08\u00a0\u00b1\u00a03.2 |\n| Carboplatin | 1.05\u00a0\u00b1\u00a00.1 | 15.02\u00a0\u00b1\u00a01.4 | 36.65\u00a0\u00b1\u00a02.5 |", "data": [[{"meta": {"name": "", "symbol": "1", "chemical formula": ""}, "etc": [{"property name": "Anti-proliferative Effects", "value": "CAL-51: 0.52 \u00b1 0.02, MDA-MB-231: 18.89 \u00b1 1.23, MCF-7: 30.88 \u00b1 2.56", "unit": "", "condition": ""}]}, {"meta": {"name": "", "symbol": "2", "chemical formula": ""}, "etc": [{"property name": "Anti-proliferative Effects", "value": "CAL-51: 0.37 \u00b1 0.04, MDA-MB-231: 10.98 \u00b1 0.95, MCF-7: 25.59 \u00b1 2.10", "unit": "", "condition": ""}]}, {"meta": {"name": "", "symbol": "3", "chemical formula": ""}, "etc": [{"property name": "Anti-proliferative Effects", "value": "CAL-51: 0.08 \u00b1 0.004, MDA-MB-231: 8.35 \u00b1 0.55, MCF-7: 17.08 \u00b1 1.64", "unit": "", "condition": ""}]}, {"meta": {"name": "", "symbol": "4", "chemical formula": ""}, "etc": [{"property name": "Anti-proliferative Effects", "value": "CAL-51: 0.69 \u00b1 0.04, MDA-MB-231: 4.92 \u00b1 0.36, MCF-7: 18.99 \u00b1 1.54", "unit": "", "condition": ""}]}, {"meta": {"name": "", "symbol": "5", "chemical formula": ""}, "etc": [{"property name": "Anti-proliferative Effects", "value": "CAL-51: 0.27 \u00b1 0.02, MDA-MB-231: 9.33 \u00b1 0.84, MCF-7: 20.32 \u00b1 2.01", "unit": "", "condition": ""}]}, {"meta": {"name": "Copper salt", "symbol": "", "chemical formula": ""}, "etc": [{"property name": "Anti-proliferative Effects", "value": "CAL-51: >100, MDA-MB-231: >100, MCF-7: >100", "unit": "", "condition": ""}]}, {"meta": {"name": "OH-PIP", "symbol": "", "chemical formula": ""}, "etc": [{"property name": "Anti-proliferative Effects", "value": "CAL-51: 18.51 \u00b1 1.5, MDA-MB-231: 22.84 \u00b1 2.1, MCF-7: 68.08 \u00b1 3.2", "unit": "", "condition": ""}]}, {"meta": {"name": "Carboplatin", "symbol": "", "chemical formula": ""}, "etc": [{"property name": "Anti-proliferative Effects", "value": "CAL-51: 1.05 \u00b1 0.1, MDA-MB-231: 15.02 \u00b1 1.4, MCF-7: 36.65 \u00b1 2.5", "unit": "", "condition": ""}]}]], "include_properties": ["etc"], "intermediate_step": {"table-convert2MD": "[gpt.ft]Table 1. Anti-proliferative Effects of Complexes 1\u20135 against Various Breast Cancer Cells\n\n| Complex | CAL-51     | MDA-MB-231 | MCF-7      |\n|---------|------------|------------|------------|\n| 1       | 0.52\u00a0\u00b1\u00a00.02 | 18.89\u00a0\u00b1\u00a01.23 | 30.88\u00a0\u00b1\u00a02.56 |\n| 2       | 0.37\u00a0\u00b1\u00a00.04 | 10.98\u00a0\u00b1\u00a00.95 | 25.59\u00a0\u00b1\u00a02.10 |\n| 3       | 0.08\u00a0\u00b1\u00a00.004 | 8.35\u00a0\u00b1\u00a00.55 | 17.08\u00a0\u00b1\u00a01.64 |\n| 4       | 0.69\u00a0\u00b1\u00a00.04 | 4.92\u00a0\u00b1\u00a00.36 | 18.99\u00a0\u00b1\u00a01.54 |\n| 5       | 0.27\u00a0\u00b1\u00a00.02 | 9.33\u00a0\u00b1\u00a00.84 | 20.32\u00a0\u00b1\u00a02.01 |\n| Copper salt | >100 | >100 | >100 |\n| OH-PIP  | 18.51\u00a0\u00b1\u00a01.5 | 22.84\u00a0\u00b1\u00a02.1 | 68.08\u00a0\u00b1\u00a03.2 |\n| Carboplatin | 1.05\u00a0\u00b1\u00a00.1 | 15.02\u00a0\u00b1\u00a01.4 | 36.65\u00a0\u00b1\u00a02.5 |\n<END>", "table-categorize": "Property", "table-property-type": "['etc']", "table-property-extract": "```JSON\n[\n    {\n        \"meta\": {\n            \"name\": \"\",\n            \"symbol\": \"1\",\n            \"chemical formula\": \"\",\n        },\n        \"etc\": [\n            {\n                \"property name\": \"Anti-proliferative Effects\",\n                \"value\": \"CAL-51: 0.52 \u00b1 0.02, MDA-MB-231: 18.89 \u00b1 1.23, MCF-7: 30.88 \u00b1 2.56\",\n                \"unit\": \"\",\n                \"condition\": \"\",\n            },\n        ],\n    },\n    {\n        \"meta\": {\n            \"name\": \"\",\n            \"symbol\": \"2\",\n            \"chemical formula\": \"\",\n        },\n        \"etc\": [\n            {\n                \"property name\": \"Anti-proliferative Effects\",\n                \"value\": \"CAL-51: 0.37 \u00b1 0.04, MDA-MB-231: 10.98 \u00b1 0.95, MCF-7: 25.59 \u00b1 2.10\",\n                \"unit\": \"\",\n                \"condition\": \"\",\n            },\n        ],\n    },\n    {\n        \"meta\": {\n            \"name\": \"\",\n            \"symbol\": \"3\",\n            \"chemical formula\": \"\",\n        },\n        \"etc\": [\n            {\n                \"property name\": \"Anti-proliferative Effects\",\n                \"value\": \"CAL-51: 0.08 \u00b1 0.004, MDA-MB-231: 8.35 \u00b1 0.55, MCF-7: 17.08 \u00b1 1.64\",\n                \"unit\": \"\",\n                \"condition\": \"\",\n            },\n        ],\n    },\n    {\n        \"meta\": {\n            \"name\": \"\",\n            \"symbol\": \"4\",\n            \"chemical formula\": \"\",\n        },\n        \"etc\": [\n            {\n                \"property name\": \"Anti-proliferative Effects\",\n                \"value\": \"CAL-51: 0.69 \u00b1 0.04, MDA-MB-231: 4.92 \u00b1 0.36, MCF-7: 18.99 \u00b1 1.54\",\n                \"unit\": \"\",\n                \"condition\": \"\",\n            },\n        ],\n    },\n    {\n        \"meta\": {\n            \"name\": \"\",\n            \"symbol\": \"5\",\n            \"chemical formula\": \"\",\n        },\n        \"etc\": [\n            {\n                \"property name\": \"Anti-proliferative Effects\",\n                \"value\": \"CAL-51: 0.27 \u00b1 0.02, MDA-MB-231: 9.33 \u00b1 0.84, MCF-7: 20.32 \u00b1 2.01\",\n                \"unit\": \"\",\n                \"condition\": \"\",\n            },\n        ],\n    },\n    {\n        \"meta\": {\n            \"name\": \"Copper salt\",\n            \"symbol\": \"\",\n            \"chemical formula\": \"\",\n        },\n        \"etc\": [\n            {\n                \"property name\": \"Anti-proliferative Effects\",\n                \"value\": \"CAL-51: >100, MDA-MB-231: >100, MCF-7: >100\",\n                \"unit\": \"\",\n                \"condition\": \"\",\n            },\n        ],\n    },\n    {\n        \"meta\": {\n            \"name\": \"OH-PIP\",\n            \"symbol\": \"\",\n            \"chemical formula\": \"\",\n        },\n        \"etc\": [\n            {\n                \"property name\": \"Anti-proliferative Effects\",\n                \"value\": \"CAL-51: 18.51 \u00b1 1.5, MDA-MB-231: 22.84 \u00b1 2.1, MCF-7: 68.08 \u00b1 3.2\",\n                \"unit\": \"\",\n                \"condition\": \"\",\n            },\n        ],\n    },\n    {\n        \"meta\": {\n            \"name\": \"Carboplatin\",\n            \"symbol\": \"\",\n            \"chemical formula\": \"\",\n        },\n        \"etc\": [\n            {\n                \"property name\": \"Anti-proliferative Effects\",\n                \"value\": \"CAL-51: 1.05 \u00b1 0.1, MDA-MB-231: 15.02 \u00b1 1.4, MCF-7: 36.65 \u00b1 2.5\",\n                \"unit\": \"\",\n                \"condition\": \"\",\n            },\n        ],\n    },\n]\n```"}}, {"idx": 7, "type": "figure", "classification": null, "content": "<fig fig-type=\"figure\" id=\"fig1\" position=\"float\">\n<label>1</label>\n<caption>\n<p>Molecular structures\nof complexes <bold>1</bold>\u2013<bold>5</bold>, dissociative small\nmolecules and nonessential H atoms.</p>\n</caption>\n<graphic id=\"gr1\" position=\"float\" xlink:href=\"ml9b00284_0001.tif\"></graphic>\n</fig>", "clean_text": " 1  Molecular structures of complexes 1-5, dissociative small molecules and nonessential H atoms.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 12, "type": "figure", "classification": null, "content": "<fig fig-type=\"figure\" id=\"fig2\" position=\"float\">\n<label>2</label>\n<caption>\n<p>Copper complexes inhibit proteasomal CT-like activity <italic>in\nvitro.</italic> Purified 20S proteasome was incubated in the presence\nof increasing concentration of copper salt, ligand, and copper complexes <bold>1</bold>\u2013<bold>5</bold> and the CT-like activity measured\nby the production of fluorescent AMC groups from Suc-LLVY-AMC substrate.\nData represent the average \u00b1 SD of three independent experiments.</p>\n</caption>\n<graphic id=\"gr2\" position=\"float\" xlink:href=\"ml9b00284_0002.tif\"></graphic>\n</fig>", "clean_text": " 2  Copper complexes inhibit proteasomal CT-like activity in vitro. Purified 20S proteasome was incubated in the presence of increasing concentration of copper salt, ligand, and copper complexes 1-5 and the CT-like activity measured by the production of fluorescent AMC groups from Suc-LLVY-AMC substrate. Data represent the average \u00b1 SD of three independent experiments.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 15, "type": "figure", "classification": null, "content": "<fig fig-type=\"figure\" id=\"fig3\" position=\"float\">\n<label>3</label>\n<caption>\n<p>Copper complexes induce apoptosis in TNBC MDA-MB-231 cells.\nCells\nwere treated with the copper complexes at 1 \u00d7 and 2 \u00d7 IC<sub>50</sub> concentrations for 24 h and apoptosis detected by flow cytometry\nusing annexin V (<italic>x</italic> axis)\u2013propidium iodide\n(<italic>y</italic> axis) staining. Early apoptotic cells (annexin\nV-positive, propidium iodide-negative) appear in the lower right quadrant\nand late apoptotic cells (positive for both markers) in the upper\nright quadrant. The percentage of cells in apoptotic quadrants is\nshown. Cytometry plots are representative of three independent experiments.\nHistogram indicates average apoptosis (both early and late) \u00b1\nSD from three independent experiments.</p>\n</caption>\n<graphic id=\"gr3\" position=\"float\" xlink:href=\"ml9b00284_0003.tif\"></graphic>\n</fig>", "clean_text": " 3  Copper complexes induce apoptosis in TNBC MDA-MB-231 cells. Cells were treated with the copper complexes at 1 \u00d7 and 2 \u00d7 IC50 concentrations for 24 h and apoptosis detected by flow cytometry using annexin V (x axis)-propidium iodide (y axis) staining. Early apoptotic cells (annexin V-positive, propidium iodide-negative) appear in the lower right quadrant and late apoptotic cells (positive for both markers) in the upper right quadrant. The percentage of cells in apoptotic quadrants is shown. Cytometry plots are representative of three independent experiments. Histogram indicates average apoptosis (both early and late) \u00b1 SD from three independent experiments.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 16, "type": "figure", "classification": null, "content": "<fig fig-type=\"figure\" id=\"fig4\" position=\"float\">\n<label>4</label>\n<caption>\n<p>Copper\ncomplexes induce apoptosis in TNBC CAL-51 cells. Cells were\ntreated with copper complexes at 1 \u00d7 and 2 \u00d7 IC<sub>50</sub> concentrations for 24 h and apoptosis detected by flow cytometry\nusing annexin V (<italic>x</italic> axis)\u2013propidium iodide\n(<italic>y</italic> axis) staining. Early apoptotic cells (annexin\nV-positive, propidium iodide-negative) appear in the lower right quadrant\nand late apoptotic cells (positive for both markers) in the upper\nright quadrant. Percentage of cells in apoptotic quadrants is shown.\nCytometry plots are representative of three independent experiments.\nHistogram indicates average apoptosis (both early and late) \u00b1\nSD from three independent experiments.</p>\n</caption>\n<graphic id=\"gr4\" position=\"float\" xlink:href=\"ml9b00284_0004.tif\"></graphic>\n</fig>", "clean_text": " 4  Copper complexes induce apoptosis in TNBC CAL-51 cells. Cells were treated with copper complexes at 1 \u00d7 and 2 \u00d7 IC50 concentrations for 24 h and apoptosis detected by flow cytometry using annexin V (x axis)-propidium iodide (y axis) staining. Early apoptotic cells (annexin V-positive, propidium iodide-negative) appear in the lower right quadrant and late apoptotic cells (positive for both markers) in the upper right quadrant. Percentage of cells in apoptotic quadrants is shown. Cytometry plots are representative of three independent experiments. Histogram indicates average apoptosis (both early and late) \u00b1 SD from three independent experiments.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 18, "type": "figure", "classification": null, "content": "<fig fig-type=\"figure\" id=\"fig5\" position=\"float\">\n<label>5</label>\n<caption>\n<p>Complexes <bold>3</bold> and <bold>5</bold> induce accumulation\nof ubiquitinated proteins and apoptosis. Breast cancer MDA-MB-231\nand CAL-51 cells were treated with <bold>3</bold> and <bold>5</bold> at 1 \u00d7 and 2 \u00d7 IC<sub>50</sub> concentrations for 24 h\nand ubiquitinated proteins, Caspase-3, PARP, Bcl-2, and Bax proteins\ndetected by Western blotting. Housekeeping GAPDH levels were used\nto confirm equal protein loading. Arrow indicates molecular mass in\nkDa. Band intensity was quantified using ImageJ and shown as the average\n\u00b1 SD (<italic>n</italic> = 3), *<italic>P</italic> &lt; 0.05.</p>\n</caption>\n<graphic id=\"gr5\" position=\"float\" xlink:href=\"ml9b00284_0005.tif\"></graphic>\n</fig>", "clean_text": " 5  Complexes 3 and 5 induce accumulation of ubiquitinated proteins and apoptosis. Breast cancer MDA-MB-231 and CAL-51 cells were treated with 3 and 5 at 1 \u00d7 and 2 \u00d7 IC50 concentrations for 24 h and ubiquitinated proteins, Caspase-3, PARP, Bcl-2, and Bax proteins detected by Western blotting. Housekeeping GAPDH levels were used to confirm equal protein loading. Arrow indicates molecular mass in kDa. Band intensity was quantified using ImageJ and shown as the average \u00b1 SD (n = 3), *P < 0.05.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 20, "type": "figure", "classification": null, "content": "<fig fig-type=\"figure\" id=\"fig6\" position=\"float\">\n<label>6</label>\n<caption>\n<p>Complexes <bold>3</bold> and <bold>5</bold> decrease stem cell\nmarkers in MDA-MB-231 cells. Breast cancer MDA-MB-231 cells were treated\nwith <bold>3</bold> and <bold>5</bold> at 0.5 \u00d7, 1 \u00d7, and\n2 \u00d7 IC<sub>50</sub> concentrations for 24 h, and the percentage\nof the CD44<sup>+</sup>/CD24<sup>\u2013</sup> cell subpopulation\nwas determined by flow cytometry. Histogram indicates the average\npercentage of the CD44<sup>+</sup>/CD24<sup>\u2013</sup> cell subpopulation\nfrom three independent experiments.</p>\n</caption>\n<graphic id=\"gr6\" position=\"float\" xlink:href=\"ml9b00284_0006.tif\"></graphic>\n</fig>", "clean_text": " 6  Complexes 3 and 5 decrease stem cell markers in MDA-MB-231 cells. Breast cancer MDA-MB-231 cells were treated with 3 and 5 at 0.5 \u00d7, 1 \u00d7, and 2 \u00d7 IC50 concentrations for 24 h, and the percentage of the CD44+/CD24- cell subpopulation was determined by flow cytometry. Histogram indicates the average percentage of the CD44+/CD24- cell subpopulation from three independent experiments.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 22, "type": "figure", "classification": null, "content": "<fig fig-type=\"figure\" id=\"fig7\" position=\"float\">\n<label>7</label>\n<caption>\n<p>Complexes <bold>3</bold> and <bold>5</bold> decrease stem cell\nmarker ALDH in MDA-MB-231 cells. Breast cancer MDA-MB-231 cells were\ntreated with <bold>3</bold> and <bold>5</bold> at 0.5 \u00d7 , 1 \u00d7,\nand 2 \u00d7 IC<sub>50</sub> concentrations for 24 h and the percentage\nof ALDH<sup>+</sup> cells determined by flow cytometry. In order to\nbetter visualize ALDH<sup>+</sup> cells, two-dimensional plots were\nobtained. SSC, side scatter channel. Histogram indicates the average\npercentage of the ALDH<sup>+</sup> cell subpopulation from three independent\nexperiments.</p>\n</caption>\n<graphic id=\"gr7\" position=\"float\" xlink:href=\"ml9b00284_0007.tif\"></graphic>\n</fig>", "clean_text": " 7  Complexes 3 and 5 decrease stem cell marker ALDH in MDA-MB-231 cells. Breast cancer MDA-MB-231 cells were treated with 3 and 5 at 0.5 \u00d7 , 1 \u00d7, and 2 \u00d7 IC50 concentrations for 24 h and the percentage of ALDH+ cells determined by flow cytometry. In order to better visualize ALDH+ cells, two-dimensional plots were obtained. SSC, side scatter channel. Histogram indicates the average percentage of the ALDH+ cell subpopulation from three independent experiments.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 23, "type": "figure", "classification": null, "content": "<fig fig-type=\"figure\" id=\"fig8\" position=\"float\">\n<label>8</label>\n<caption>\n<p>Complexes <bold>3</bold> and <bold>5</bold> decrease\nstem cell\nmarker ALDH in CAL-51 cells. Breast cancer CAL-51 cells were treated\nwith <bold>3</bold> and <bold>5</bold> at 0.5 \u00d7 , 1 \u00d7, and\n2 \u00d7 IC<sub>50</sub> concentrations for 24 h and the percentage\nof ALDH<sup>+</sup> cells determined by flow cytometry. In order to\nbetter visualize ALDH<sup>+</sup> cells, two-dimensional plots were\nobtained. SSC, side scatter channel. Histogram indicates the average\npercentage of the ALDH<sup>+</sup> cell subpopulation from three independent\nexperiments.</p>\n</caption>\n<graphic id=\"gr8\" position=\"float\" xlink:href=\"ml9b00284_0008.tif\"></graphic>\n</fig>", "clean_text": " 8  Complexes 3 and 5 decrease stem cell marker ALDH in CAL-51 cells. Breast cancer CAL-51 cells were treated with 3 and 5 at 0.5 \u00d7 , 1 \u00d7, and 2 \u00d7 IC50 concentrations for 24 h and the percentage of ALDH+ cells determined by flow cytometry. In order to better visualize ALDH+ cells, two-dimensional plots were obtained. SSC, side scatter channel. Histogram indicates the average percentage of the ALDH+ cell subpopulation from three independent experiments.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 26, "type": "figure", "classification": null, "content": "<fig fig-type=\"figure\" id=\"fig9\" position=\"float\">\n<label>9</label>\n<caption>\n<p>Schematic\nrepresentation of the proposed binding modes for complexes <bold>1</bold>\u2013<bold>5</bold> with proteasome (PDB ID:<ext-link ext-link-type=\"pdb\" xlink:href=\"3MG6\">3MG6</ext-link>). Only amino acids\nlocated within 4 \u00c5 of the bound ligand are displayed and labeled.\nKey H-bonds between the complexes and the protein are shown as dashed\nyellow lines.</p>\n</caption>\n<graphic id=\"gr9\" position=\"float\" xlink:href=\"ml9b00284_0009.tif\"></graphic>\n</fig>", "clean_text": " 9  Schematic representation of the proposed binding modes for complexes 1-5 with proteasome (PDB ID:3MG6). Only amino acids located within 4 \u00c5 of the bound ligand are displayed and labeled. Key H-bonds between the complexes and the protein are shown as dashed yellow lines.   ", "data": null, "include_properties": null, "intermediate_step": {}}], "metadata": {"doi": "10.1021/acsmedchemlett.9b00284", "title": "\nNovel Copper Complexes That Inhibit the Proteasome\nand Trigger Apoptosis in Triple-Negative Breast Cancer Cells\n", "journal": "American Chemical\nSociety", "date": "2019.07", "author_list": ["Li\nDong-Dong", "Yagu\u0308e\nErnesto", "Wang\nLu-Yao", "Dai\nLin-Lin", "Yang\nZi-Bo", "Zhi\nShuang", "Zhang\nNa", "Zhao\nXiu-Mei", "Hu\nYun-Hui"]}}